Next Article in Journal
MDM2-Mediated p21 Proteasomal Degradation Promotes Fluoride Toxicity in Ameloblasts
Previous Article in Journal
Rho GTPases—Emerging Regulators of Glucose Homeostasis and Metabolic Health
Previous Article in Special Issue
Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators as a Therapy for Glioblastoma
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview

Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target

1,†, 1,2,† and 1,3,*
1
Department of Plant Pathology and Microbiology, National Taiwan University, Taipei 10617, Taiwan
2
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
3
Center for Biotechnology, National Taiwan University, Taipei 10617, Taiwan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2019, 8(5), 435; https://doi.org/10.3390/cells8050435
Received: 30 March 2019 / Revised: 2 May 2019 / Accepted: 9 May 2019 / Published: 10 May 2019
(This article belongs to the Special Issue Epidermal Growth Factor Receptor Signaling)
  |  
PDF [789 KB, uploaded 10 May 2019]
  |  

Abstract

The partner of activated epidermal growth factor receptor (EGFR), growth factor receptor bound protein-7 (Grb7), a functionally multidomain adaptor protein, has been demonstrated to be a pivotal regulator for varied physiological and pathological processes by interacting with phospho-tyrosine-related signaling molecules to affect the transmission through a number of signaling pathways. In particular, critical roles of Grb7 in erythroblastic leukemia viral oncogene homolog (ERBB) family-mediated cancer development and malignancy have been intensively evaluated. The overexpression of Grb7 or the coamplification/cooverexpression of Grb7 and members of the ERBB family play essential roles in advanced human cancers and are associated with decreased survival and recurrence of cancers, emphasizing Grb7′s value as a prognostic marker and a therapeutic target. Peptide inhibitors of Grb7 are being tested in preclinical trials for their possible therapeutic effects. Here, we review the molecular, functional, and clinical aspects of Grb7 in ERBB family-mediated cancer development and malignancy with the aim to reveal alternative and effective therapeutic strategies. View Full-Text
Keywords: growth factor receptor bound protein-7; ERBB family; epidermal growth factor receptor; cancer development; prognostic marker; therapeutic target growth factor receptor bound protein-7; ERBB family; epidermal growth factor receptor; cancer development; prognostic marker; therapeutic target
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Chu, P.-Y.; Tai, Y.-L.; Shen, T.-L. Grb7, a Critical Mediator of EGFR/ErbB Signaling, in Cancer Development and as a Potential Therapeutic Target. Cells 2019, 8, 435.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top